
Vita Fedele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3752865/publications.pdf Version: 2024-02-01



VITA FEDELE

#	Article	IF	CITATIONS
1	Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. Nature Communications, 2018, 9, 1028.	12.8	98
2	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology, 2021, 11, 638360.	2.8	42
3	A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093788.	3.2	28
4	Permissive State of EMT: The Role of Immune Cell Compartment. Frontiers in Oncology, 2020, 10, 587.	2.8	19
5	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4661-4669.	7.0	18
6	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. Cancers, 2020, 12, 3299.	3.7	14
7	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094796.	3.2	9
8	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Npj Breast Cancer, 2021, 7, 118.	5.2	3